Iovance Biotherapeutics is trading at $14.55, up 6.83%; no verified October 19 company announcement clearly explains the rise.
- The latest company press-release listing shows no new release for October 19.
- Nasdaq strength may be supportive, but available evidence does not establish it as the direct cause of Iovance’s gain.
- Recent analyst optimism and the September revenue-guidance increase are prior context, not confirmed new catalysts for October 19.